| Business Summary | | Penwest
Pharmaceuticals
Co.
is
engaged
in
the
research,
development
and
commercialization
of
novel
drug
delivery
technologies
and
has
expertise
in
developing,
manufacturing
and
selling
excipient
ingredients
for
the
pharmaceutical
industry.
Based
on
its
fundamental
expertise
in
tabletting
ingredients,
the
Company
has
developed
its
proprietary
Timerx
controlled-release
drug
delivery
technology,
which
is
applicable
to
a
broad
range
of
orally
administered
drugs,
and
ProSolv,
a
co-processing
drug
delivery
technology
platform.
The
Company
is
utilizing
the
Timerx
system
to
formulate
generic
versions
of
branded
controlled-release
drugs,
controlled-release
formulations
of
marketed
immediate-release
drugs
and
New
Chemical
Entities.
The
Company
is
also
engaged
in
the
development,
production
and
distribution
of
branded
pharmaceutical
excipients,
which
are
the
inactive
components
included
in
tablets
and
capsules. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Penwest
Pharmaceuticals
Co.
is
engaged
in
the
research,
development
and
commercialization
of
novel
drug
delivery
technologies.
The
Company
also
manufactures
and
distributes
excipients.
For
the
six
months
ended
6/30/01,
revenues
rose
1%
to
$20.5
million.
Net
loss
before
acct.
change
rose
55%
to
$5.3
million.
Revenues
reflect
higher
royalties
earned
on
Mylan's
sales
of
the
30
mg
strength
of
generic
Procadia
XL.
Higher
loss
reflects
increased
professional
fees. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Tod Hamachek, 55 Chairman
of Directors and CEO | $406K | -- | Jennifer Good, 36 CFO,
VP-Fin. | 196K | -- | Anand Baichwal, Ph.D, 46 Sr.
VP of R&D | 225K | -- | Stephen Berte, Jr., 45 Gen.
Mang., Excipients Bus. | 182K | $29K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|